Abstract
Gallbladder cancer is an aggressive malignancy that is associated with a poor prognosis. While surgical resection provides the only curative option, the majority of patients are not considered resectable due to the presence of metastatic disease at the time of presentation. As systemic therapeutic options improve, a treatment dilemma can arise in patients treated with upfront chemotherapy with responsive disease and regionally metastatic disease that is resectable. We present a patient with regionally metastatic gallbladder cancer to segment IVb of the liver with responsive disease after gemcitabine/cisplatin treatment who underwent a radical cholecystectomy and central hepatectomy resulting in a prolonged disease-free interval.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
